^
    23h
    BGB-3111-215t: Zanubrutinib (BGB-3111) in Participants With Previously Treated B-Cell Lymphoma Intolerant of Prior Bruton Tyrosine Kinase Inhibitor (BTKi) Treatment (clinicaltrials.gov)
    P2, N=90, Active, not recruiting, BeiGene | Trial completion date: Oct 2025 --> Dec 2025 | Trial primary completion date: Oct 2025 --> Dec 2025
    Trial completion date • Trial primary completion date
    |
    Imbruvica (ibrutinib) • Brukinsa (zanubrutinib) • Calquence (acalabrutinib)
    24h
    ALICIA(BY): Observ Prosp Study of Acalabrutinib in CLL Therapy in Real Clinical Practice in Belarus (clinicaltrials.gov)
    P=N/A, N=50, Not yet recruiting, AstraZeneca
    New trial
    |
    Calquence (acalabrutinib)
    2d
    Zanubrutinib and Acalabrutinib Use and Risk of Atrial Fibrillation in Patients With Chronic B-cell Malignancies (clinicaltrials.gov)
    P=N/A, N=15000, Not yet recruiting, University Hospital, Caen
    New trial
    |
    Brukinsa (zanubrutinib) • Calquence (acalabrutinib)
    7d
    A Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Acalabrutinib in Adults With Previously Untreated Chronic Lymphocytic Leukemia (clinicaltrials.gov)
    P3, N=500, Not yet recruiting, BeOne Medicines
    New P3 trial
    |
    Venclexta (venetoclax) • Brukinsa (zanubrutinib) • Calquence (acalabrutinib) • sonrotoclax (BGB-11417)
    7d
    KEYNOTE145: ACP-196 (Acalabrutinib) in Combination With Pembrolizumab, for Treatment of Hematologic Malignancies (clinicaltrials.gov)
    P1/2, N=161, Completed, Acerta Pharma BV | Active, not recruiting --> Completed | Trial completion date: Apr 2026 --> Oct 2025
    Trial completion • Trial completion date
    |
    Keytruda (pembrolizumab) • Calquence (acalabrutinib)
    8d
    Is Bruton tyrosine kinase a potential target to treat mast cell neoplasms? Systemic mastocytosis associated with chronic lymphoid leukemia successfully treated with acalabrutinib monotherapy: a case report and review of the literature. (PubMed, Haematologica)
    Not available.
    Journal
    |
    BTK (Bruton Tyrosine Kinase)
    |
    Calquence (acalabrutinib)
    9d
    Acalabrutinib (ACP-196) in Combination With ACP-319, for Treatment of B-Cell Malignancies (clinicaltrials.gov)
    P1/2, N=40, Completed, Acerta Pharma BV | Active, not recruiting --> Completed | Trial completion date: Apr 2026 --> Oct 2025
    Trial completion • Trial completion date
    |
    Calquence (acalabrutinib) • ACP-319
    13d
    ACALA-R In Predominantly Demyelinating IgM Mediated Neuropathy (clinicaltrials.gov)
    P2, N=12, Active, not recruiting, Shayna Sarosiek, MD | Recruiting --> Active, not recruiting | N=33 --> 12
    Enrollment closed • Enrollment change
    |
    CD20 (Membrane Spanning 4-Domains A1) • CD22 (CD22 Molecule) • IL2RA (Interleukin 2 receptor, alpha) • CD5 (CD5 Molecule) • SDC1 (Syndecan 1) • CD27 (CD27 Molecule) • MME (Membrane Metalloendopeptidase) • ITGAE (Integrin Subunit Alpha E) • FCER2 (Fc Fragment Of IgE Receptor II)
    |
    Rituxan (rituximab) • Calquence (acalabrutinib)
    15d
    STAIR: STop and Restart Acalabrutinib In fRail Patients With Previously Untreated Chronic Lymphocytic Leukemia (clinicaltrials.gov)
    P2, N=160, Active, not recruiting, French Innovative Leukemia Organisation | Recruiting --> Active, not recruiting | Trial primary completion date: Jan 2026 --> Aug 2025
    Enrollment closed • Trial primary completion date
    |
    TP53 (Tumor protein P53) • IGH (Immunoglobulin Heavy Locus)
    |
    TP53 mutation • IGH mutation
    |
    Calquence (acalabrutinib)
    16d
    Phase 2 Study of BTKi-Rituximab Induction Followed by Glofitamab Consolidation in High Risk Untreated MCL Patients - WINDOW-4 Study (clinicaltrials.gov)
    P2, N=30, Not yet recruiting, M.D. Anderson Cancer Center
    New P2 trial
    |
    Rituxan (rituximab) • Brukinsa (zanubrutinib) • Calquence (acalabrutinib) • Columvi (glofitamab-gxbm)
    17d
    ASSURE: Acalabrutinib Safety Study in Untreated and Relapsed or Refractory Chronic Lymphocytic Leukemia Patients (clinicaltrials.gov)
    P3, N=552, Completed, AstraZeneca | Active, not recruiting --> Completed
    Trial completion
    |
    TP53 (Tumor protein P53) • CD20 (Membrane Spanning 4-Domains A1) • IGH (Immunoglobulin Heavy Locus) • CD5 (CD5 Molecule) • FCER2 (Fc Fragment Of IgE Receptor II)
    |
    Chr del(17p) • Chr del(11q) • IGH mutation
    |
    Calquence (acalabrutinib)
    17d
    RETAIN: Retention Rate of Acalabrutinib in a Non-interventional Setting (clinicaltrials.gov)
    P=N/A, N=137, Active, not recruiting, AstraZeneca | Recruiting --> Active, not recruiting | N=200 --> 137
    Enrollment closed • Enrollment change
    |
    Calquence (acalabrutinib)